Tweet Habek M, Adamec I, Gabelić T, Barun B, Krbot Skorić M. Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis. J Neurol. 2025 Sep 20;272(9):637. Objective: To compare the sensitivity (capacity to identify true positives), specificity (capacity to detect true negatives), predictive value, and accuracy of the 2010, 2017,…
Official statement on MS Society South Australia & Northern Territory voluntary administration
The post Official statement on MS Society South Australia & Northern Territory voluntary administration appeared first on MS Australia. Source: www.msaustralia.org.au
FDA pushes back to December its decision on Sanofi’s tolebrutinib
The U.S. Food and Drug Administration (FDA) has delayed by three months its decision on whether or not to approve Sanofi’s tolebrutinib as a treatment for multiple sclerosis (MS), pushing […] The post FDA pushes back to December its decision on Sanofi’s tolebrutinib appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Reiniciar con intención: Adaptándonos a la rutina después del verano
Volver a una rutina puede ser todo un desafío. Ya sea que regrese a la escuela, regrese de sus vacaciones de verano o simplemente desee tener más estructura en su vida, la transición a una nueva temporada puede sentirse agobiante. … Continue reading → Source: blog.mymsaa.org
Reset with Intention: Embracing Routine After Summer
Getting back into a routine can be challenging, whether you’re returning to school, coming off a summer break, or simply craving more structure. The transition into a new season, especially back-to-school time, can feel overwhelming. But it doesn’t have to … Continue reading → Source: blog.mymsaa.org
Told you so..
Tweet Salazar-Camelo A, Vega L, Fadlallah Y, Bou Rjeily N, Balshi A, Morris B, Ghajarzadeh M, Mowry EM, Waubant E, Nourbakhsh B. Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls. Mult Scler. 2025 Sep 19:13524585251375350. doi: 10.1177/13524585251375350. Epub ahead of print. PMID: 40970353. Background: Whether continuous anti-CD20 therapy is…
Ready to walk and roll the runway
Dan and I often say that our life with MS is about moving forward together. After all, Dan is walking, and I am rolling. We’re always moving forward side by side. Click this image to donate and support our MS Focus on Fashion fundraising efforts. Now, we’re taking that movement to a new kind of…
How does CD20 work?What next the Questioning B cell?
Tweet When I was a kid we had a few PC descriptors for non-heterosexual identifying people and now whe have LGBTQIA+ and an every expanding acronym. Yep you as what has this got to do with MS research. We have anti-CD20 antibodies which are increasingly used and is the major high efficacy class of treatment…
Old McDonald Had a Criteria..Ee, i, ee, i, o
Tweet ….and on that Criteria he had some neuros….Ee,i, ee,i, o with some consultancy here (This week Barcelona) and some consultancy there (Next year SanDiego), here, there, here, there, every where a…… So the McDonald Criteria for MS diagnosis has truly dropped only 2 years after it was first leaked. This means it is easier…
In MS, less frequent treatment dosing schedule is equally effective
People with multiple sclerosis (MS) may receive less frequent treatments with anti-CD20 therapies without increasing their risk of disease activity or disability progression. That’s according to a new meta-analysis of […] The post In MS, less frequent treatment dosing schedule is equally effective appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com